Thousand oaks
THOUSAND OAKS, California, November 15, 2011 -
Amgen (NASDAQ: AMGN) today announced that the European Commission (EC) has approved a variation to the marketing authorization for Vectibix (panitumumab) to include indications for the treatment of patients with wild-type KRAS metastatic colorectal cancer (mCRC) in first-line in combination with FOLFOX and in second-line in combination with FOLFIRI in patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan).
THOUSAND OAKS, California, June 24, 2011 -
Amgen (NASDAQ: AMGN) today announced that the Committee for
Medicinal Products for Human Use (CHMP) of the European Medicines
Agency (EMA) has adopted a positive opinion recommending that
Vectibix (panitumumab) be approved for use in the European Union
(EU) in first-line in combination with FOLFOX and in second-line in
combination with FOLFIRI in patients who have received first-line
fluoropyrimidine-based chemotherapy (excluding irinotecan) for
patients with wild-type KRAS metastatic colorectal cancer
(mCRC), following a successful re-examination procedure by
Amgen.
THOUSAND OAKS, California, May 20, 2011 - Amgen (Nasdaq: AMGN) today announced that the Committee for Medicinal
Products for Human Use (CHMP) of the European Medicines Agency (EMA) has
recommended a positive opinion for the marketing authorization of XGEVA(TM)
(denosumab) for the prevention of skeletal-related events (pathological
fracture, radiation to bone, spinal cord compression or surgery to bone) in
adults with bone metastases from solid tumors.
THOUSAND OAKS, California, April 8, 2011 - Amgen (NASDAQ: AMGN), the world's largest biotechnology company,
announced today the expansion of its operations in Brazil, including the
acquisition of Bergamo, a privately-held Brazilian pharmaceutical company.
THOUSAND OAKS, California, March 30, 2011 - Amgen (Nasdaq: AMGN) announced today that it has submitted a request to
the European Medicines Agency (EMA) for a re-examination of the negative
opinion issued in March by the Committee For Medicinal Products for Human Use
(CHMP) for the use of Vectibix in combination with chemotherapy for patients
with wild-type KRAS metastatic colorectal cancer (mCRC).
More News
- New 2-Year Open-Label Study Shows More Than 90 Percent of Patients Preferred Prolia Injection Every Six Months Over Weekly Oral Alendronate
- Prolia(R) (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial
- Amgen Statement on CHMP Opinion on Vectibix(R) (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer
- Prolia(TM) (denosumab) Receives Best New Drug Honor at Scrip Awards
- Ceres Salt-Tolerant Trait Could Unlock Millions More Acres of Marginal Cropland
- Irene McCormack Selected Xirrus for Their Ability to Provide More Bandwidth with Fewer Devices Than Any Other Wi-Fi Vendor
- Ultra High Performance Wi-Fi for Large User Populations and Temporary Deployments Further Enhances High Speed Internet Access Services
- Hayley Tabor Joins Xirrus to Rapidly Expand Global Footprint and Open New Routes to the Enterprise
- Xirrus Prepares Mondriaan College for Wireless Initiatives with No Hidden Costs
- Given as an Injection Every Six Months, Prolia Reduced the Risk of Fractures in Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fractures
- Xirrus Chosen for Their Ability to Provide More Range and Bandwidth with Fewer Devices than any Other Vendor
- Plainedge School District Deploys Xirrus 802.11n to Solve Capacity Wireless with 75% Fewer Devices
- Asheville Regional Airport Replaces Access Points with High Performance, High Density Wi-Fi Arrays from Xirrus
- Xirrus 802.11n Wi-Fi Arrays Prepare Paideia School to Support Coverage and Density Essential to a 1:1 Initiative
- Amgen Receives CHMP Positive Opinion for Prolia(TM) (Denosumab) in the European Union
- Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in First-Line Metastatic Colorectal Cancer
- Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in Second-Line Metastatic Colorectal Cancer
- Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients
- Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases
- Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 - ESMO 34 Congress
